Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00834067 · ClinicalTrials.gov registry record · Phase 1
Moexipril HCl/Hydrochlorothiazide 15/25 mg Tablets Under Non-Fasting Conditions
A Phase 1 study, sponsored by Teva Pharmaceuticals USA.
- Completed
- Registry status
- Phase 1
- Development phase
- 60
- Enrollment target
NCT00834067: Completed Phase 1 study, sponsored by Teva Pharmaceuticals USA.
NCT00834067 is a Phase 1 study that has completed, run by Teva Pharmaceuticals USA. The registered enrollment target is 60 participants, roughly in line with the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00834067, a Phase 1 study, has completed, sponsored by Teva Pharmaceuticals USA.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 60 participants
- Enrollment target
Study Summary
The objective of this study is to compare the relative bioavailability of moexipril HCl/ hydrochlorothiazide 15/25 mg tablets (manufactured and distributed by TEVA Pharmaceuticals USA) with that of UNIRETIC® 15/25 mg tablets (Schwartz Pharma) in healthy, adult, non-smoking subjects under non-fasting conditions.
Primary Outcome
Bioequivalence based on Cmax.
Interventions
- DRUG Moexipril HCl/hydrochlorothiazide 15/25 mg tablets
- DRUG UNIRETIC® 15/25 mg tablets
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2003-10 |
| Est. Completion | 2003-11 |
| Phase | Phase 1 |
What the finished NCT00834067 record still lists
NCT00834067 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, roughly in line with the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target.
The record links to 0 conditions, and to 2 interventions - of which Moexipril HCl/hydrochlorothiazide 15/25 mg tablets is the first listed.
NCT00834067 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00834067 about?
NCT00834067 is a clinical study titled "Moexipril HCl/Hydrochlorothiazide 15/25 mg Tablets Under Non-Fasting Conditions". The objective of this study is to compare the relative bioavailability of moexipril HCl/ hydrochlorothiazide 15/25 mg tablets (manufactured and distributed by TEVA Pharmaceuticals USA) with that of UNIRETIC® 15/25 mg tablets (Schwartz Pharma) in healthy, adult, non-smoking subjects under non-fasting...
What is the current status of trial NCT00834067?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 60 participants. The study started on 2003-10. Estimated completion is 2003-11.
What interventions are being tested in trial NCT00834067?
The interventions under investigation include: Moexipril HCl/hydrochlorothiazide 15/25 mg tablets (DRUG), UNIRETIC® 15/25 mg tablets (DRUG).
Who is sponsoring clinical trial NCT00834067?
This trial is sponsored by Teva Pharmaceuticals USA, which has 83 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00834067's enrollment target sits among peer trials
60 831st of 2000 higher than 1,106 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia